Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Phase II efficacy results for ABT-436 in alcohol-dependent subjects

Oct. 3, 2016

NIH dopamine D3 receptor antagonist VK-4-116 active in substance abuse models

Sep. 12, 2016

Insys Therapeutics enrolls first patient in phase II trial of canabidiol

Aug. 19, 2016

Promising phase III topline results for RBP-6000 monthly depot to treat opioid use disorder

Aug. 17, 2016

Embera Neurotherapeutics receives grant to continue development of drug for cocaine addition

July 27, 2016

Cerecor announces research grant for the development of CERC-501

July 27, 2016

Cerecor awarded grant from NIAAA

July 21, 2016

Addex Therapeutics reports positive results on ADX-71441

June 10, 2016

FDA awards fast track designation to Indivior's RBP-6000 buprenorphine monthly depot

May 27, 2016

FDA approves Probuphine for opioid dependence

May 27, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...